http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 06:07:02 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/27027317.html <p>BofA Securities analyst Charlie Haywood reiterated a Buy rating and EUR280.00 price target on UCB (UCB:BB) (OTC: UCBJY).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/27027317.html Fri, 04 Sep 2026 06:07:02 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/27027317.html <p>BofA Securities analyst Charlie Haywood reiterated a Buy rating and EUR280.00 price target on UCB (UCB:BB) (OTC: UCBJY).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/27027317.html Fri, 04 Sep 2026 06:07:02 -0400 UCBJY http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/Press+Releases/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html <div class="xn-content"> <p><i>Recognition reflects employee feedback and comes as <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location> footprint through a <money>$2 billion</money> investment in a new biomanufacturing campus expected to create more than 330 jobs.</i></p><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 16, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company with its <location value="LC/us" idsrc="xmltag.org" >U.S</location>. headquarters in metro <location value="LU/us.ga.atlnta" idsrc="xmltag.org" >Atlanta</location>, has been named a winner of the <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4752874-1&amp;h=79209650&amp;u=https%3A%2F%2Flinkprotect.cudasvc.com%2Furl%3Fa%3Dhttps%253a%252f%252ftopworkplaces.com%252faward%252fatlanta%252f2026%252f150-499%252f4598%252f%253fpage%253d2%26c%3DE%2C1%2CYl4bhCuIrGACvplhPomIHWrheWHXSSi3Lv69SjxAd3rwpOyWdkfwq2jV2ieGQf03QBIWZL8H-uuzTG6rIcI7fqJiGLrcnd-EjaS7IdjXYg%2C%2C%26typo%3D1&amp;a=2026+Metro+Atlanta+Top+Workplaces+Award+by+Axios" target="_blank" rel="nofollow">2026 Metro Atlanta Top Workplaces Award by Axios</a>. As <span value="EuronextBrussels:UCB" idsrc="xmltag.org">UCB</span> expands its presence in <location value="LS/us.ga" idsrc="xmltag.org" >Georgia</location>, the Top Workplaces award reinforces the company's http://www.streetinsider.com/PRNewswire/Axios+Names+UCB+a+Winner+of+the+Metro+Atlanta+Top+Workplaces+2026+Award/26933544.html Sun, 16 Aug 2026 08:05:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/Press+Releases/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html <div class="xn-content"> <ul type="disc"><li>FINTEPLA is approved by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹</li><li>Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²</li><li>Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²</li><li>Safety findings were consistent with known data, http://www.streetinsider.com/PRNewswire/Epilepsia+Open+publishes+results+of+post+hoc+data+analysis+of+FINTEPLA%C2%AE+%28fenfluramine%29+in+patients+with+Lennox-Gastaut+syndrome/26871998.html Wed, 05 Aug 2026 10:40:00 -0400 A.06822034 O.19039711 O.20026344 UCB UCBJY http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/26860348.html <p>UBS analyst Xian Deng reiterated a Buy rating and EUR310.00 price target on UCB (UCB:BB) (OTC: UCBJY).</p> http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/26860348.html Tue, 04 Aug 2026 05:33:42 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/26860348.html <p>UBS analyst Xian Deng reiterated a Buy rating and EUR310.00 price target on UCB (UCB:BB) (OTC: UCBJY).</p> http://www.streetinsider.com/Intl+Ratings/UBS+Reiterates+Buy+Rating+on+UCB+%28UCB%3ABB%29+%28UCBJY%29/26860348.html Tue, 04 Aug 2026 05:33:42 -0400 UCBJY http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Lowered+to+EUR260+at+Barclays/26852532.html Barclays analyst Charles Pitman lowered the price target on UCB (UCB:BB) (OTC: UCBJY) to EUR260.00 (from EUR300.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/UCB+%28UCB%3ABB%29+%28UCBJY%29+PT+Lowered+to+EUR260+at+Barclays/26852532.html Mon, 03 Aug 2026 04:44:52 -0400 UCBJY